Cargando…

Adverse drug events affecting medication persistence with rivastigmine patch application

PURPOSE: The rivastigmine transdermal patch, the only existing cholinesterase inhibitor available as a transdermal delivery system for treating Alzheimer’s disease, has been reported to inhibit progression of cognitive impairment and impairment in activities of daily living, in addition to reducing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osada, Takashi, Watanabe, Norio, Asano, Naomitsu, Adachi, Yuzo, Yamamura, Keiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055883/ https://www.ncbi.nlm.nih.gov/pubmed/30050286 http://dx.doi.org/10.2147/PPA.S166680

Ejemplares similares

An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch
por: Grieco, T., et al.
Publicado: (2011)

Preparation and Characterization of Rivastigmine Transdermal Patch Based on Chitosan Microparticles
por: Sadeghi, Mohsen, et al.
Publicado: (2016)

Third degree atrioventricular block associated with treatment with rivastigmine transdermal patch
por: Knudtzen, Fredrikke C., et al.
Publicado: (2013)

Drug Persistency Patterns for Patients Treated With Rivastigmine or Donepezil in Usual Care Settings
por: Mauskopf, Josephine A., et al.
Publicado: (2005)

The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease
por: Kim, Hyeyun, et al.
Publicado: (2016)

Improper Application of a Rivastigmine Patch to the Back of the Neck Induced Toxic Symptoms
por: Matsuzono, Kosuke, et al.
Publicado: (2023)

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease
por: Farlow, M.R., et al.
Publicado: (2011)

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review
por: Kurz, A, et al.
Publicado: (2009)

Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice
por: López-Pousa, Secundino, et al.
Publicado: (2013)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease
por: Kim, Yong Kyun, et al.
Publicado: (2014)

A prospective study on the use of rivastigmine transdermal patch in Alzheimer’s dementia in a routine clinical setting
por: Nazir, Ejaz, et al.
Publicado: (2010)

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
por: Han, Hyun Jeong, et al.
Publicado: (2011)

Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon(®) Transdermal Patch (Daily)- A Randomized Clinical Trial
por: Schurad, Bjoern, et al.
Publicado: (2022)

A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch
por: Vagenas, Vassileios, et al.
Publicado: (2015)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

Acquired Localized Hypertrichosis Induced by Rivastigmine
por: Imbernón-Moya, Adrian, et al.
Publicado: (2016)

Pharmacist-based Donepezil Outpatient Consultation Service to improve medication persistence
por: Watanabe, Norio, et al.
Publicado: (2012)

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
por: Molinuevo, José L, et al.
Publicado: (2015)

Rivastigmine for the treatment of dementia associated with Parkinson’s disease
por: Reingold, Jennifer L, et al.
Publicado: (2007)

Rivastigmine in Chinese patients with subcortical vascular dementia
por: Mok, Vincent, et al.
Publicado: (2007)

Effects of rivastigmin tartarat in the therapy of patients with schizophrenia
por: Djordjevic, Snezana, et al.
Publicado: (2010)

Direct Asymmetric Reductive Amination for the Synthesis of (S)-Rivastigmine
por: Gao, Guorui, et al.
Publicado: (2018)

Treatment of pediatric antimuscarinic delirium with oral rivastigmine
por: Yakey, Brandtly, et al.
Publicado: (2023)

Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer’s Disease
por: Lefèvre, Gilbert, et al.
Publicado: (2016)

Zinc Chloride-Catalyzed Synthesis of Carbamates: An Application for the Synthesis of the Anti-Alzheimer’s Drug Rivastigmine
por: Gayke, Manoj, et al.
Publicado: (2022)

Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients: The Japan Adverse Drug Events Study
por: Ayani, Nobutaka, et al.
Publicado: (2021)

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life
por: Annicchiarico, Roberta, et al.
Publicado: (2007)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer's Disease
por: Nakamura, Yu, et al.
Publicado: (2011)

Effectiveness of the 10 cm(2) Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer’s Dementia: A 48-Week Real-World Observational Study
por: Chang, Chiung-Chih, et al.
Publicado: (2021)

Effects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer’s disease
por: Nakamura, Kazuhito, et al.
Publicado: (2014)

Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database
por: Asano, Hiroki, et al.
Publicado: (2023)

Analysis of Adverse Events of Cholinesterase Inhibitors and NMDA Receptor Antagonists on Arrhythmias Using the Japanese Adverse Drug Event Report Database
por: Kobayashi, Shotaro, et al.
Publicado: (2023)

Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer’s disease
por: Micca, Joseph L, et al.
Publicado: (2014)

Effectiveness, Medication Patterns, and Adverse Events of Traditional Chinese Herbal Patches for Osteoarthritis: A Systematic Review
por: Wang, Xuezong, et al.
Publicado: (2014)

Development and Validation of a Spectrofluorimetric Method for the Estimation of Rivastigmine in Formulations
por: Kapil, R., et al.
Publicado: (2009)

Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
por: Oh, Yoon-Sang, et al.
Publicado: (2015)

Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
por: dos Santos, Gustavo Alves Andrade, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jc8dfe39006qq9esub5gl0113r